Skip to content
zameds

Bupropion, naltrexone (Contrave)

Bupropion, naltrexone

Inova Pharmaceuticals (Pty) Ltd

Registration

Applicant
Inova Pharmaceuticals (Pty) Ltd
Certificate holder
Acino Pharma (Pty) Ltd
Registrations
1

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Contrave

Each Prolonged release tablet contains: Bupropion Hydrochloride 90,0 mg and Naltrexone Hydrochloride 8,0 mg

8 mg/90 mgProlonged-release tablet.52047852/11.3/0478Approved 25 April 2023RegisteredNot determinedPIPIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S5: Bupropion

    Consolidated Schedules 06 July 2026, line 9290

  • S4: Naltrexone

    Consolidated Schedules 06 July 2026, line 7208

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles